COBENFY

Jun 13, 2025

The Patent Cliff Returns: Can Big Pharma Innovate Fast Enough to Stay on Top? For decades, blockbuster drugs have fueled the pharmaceutical industry’s golden age. But as the 2020s unfold, a familiar threat is resurfacing with unprecedented intensity: the Loss of Exclusivity (LOE). With patents on multibillion-do...

Sep 30, 2024

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...